ClinicalTrials.gg
RecruitingNCT07112222Updated Jan 26, 2026

A Study of LM-350 in Subjects With Advanced Solid Tumours

A Phase 1/2 interventional study of LM-350 for injection in Malignant Tumors, sponsored by LaNova Medicines Limited. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by LaNova Medicines Limited (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350.

For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.

02

Conditions studied

  • Malignant Tumors

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 80 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

LaNova Medicines Limited is the lead sponsor of 18 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are willing to participate in the study and sign the form (ICF) prior to any procedure.
  2. Participant must be ≥18 years or the legal age of consent at the time of signing the ICF.
  3. (ECOG) performance status of 0-1.
  4. ≥ 3 months.
  5. Patients with advanced solid tumors confirmed by histopathological diagnosis who have failed standard treatment, are intolerant to standard treatment, or for whom standard treatment is currently unsuitable.
  6. Pre-treatment archived tumour tissue (within 3 years) or on-treatment tumour could be provided for biomarker analysis.
  7. Must have at least one according to v1.1.
  8. Adequate organ and bone marrow function as defined by protocol.
  9. Subjects who are able to communicate well with investigators and understand and adhere to the requirements of this study.

Exclusion criteria

Exclusion Criteria:

  1. Participate in any other clinical trial within 28 days prior to 1st dosing of LM-350.
  2. Subjects who have received treatment with the same targeting.
  3. History of ≥ Grade 3 late diarrhea during or after previous treatment with a topoisomerase inhibitor.
  4. Subjects who have received the following anti-tumor treatments within the specified time periods prior to the first dosing of LM-350.
  5. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤ grade 1 of v5.0.
  6. Subjects with uncontrolled tumour-related pain.
  7. Subjects with known central nervous system (CNS) or meningeal .
  8. Subjects who have clinically uncontrollable third-space fluid accumulation.
  9. Subjects who experienced grade 3 or higher to the treatment that contains monoclonal antibody.
  10. Subjects who take systemic (≥ 10 mg/day of prednisone or equivalents) or other systemic medications within 2 weeks prior to the first dose of LM-350.
  11. Has a history of (noninfectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
  12. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses, and any , or prior pneumonectomy.
  13. Use of any within 28 days prior to 1st dosing of LM-350.
  14. Current unstable of full-dose oral or parenteral anticoagulants or thrombolytic agents for > 2 weeks prior to the first dose of LM-350.
  15. Subjects with active or a documented history of chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease).
  16. Subjects with complete or incomplete intestinal obstruction within 3 months prior to the first dose of the study drug , orpatients who are currently at the risk of intestinal perforation.
  17. Subjects who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-350.
  18. Subjects who have severe cardiovascular disease.
  19. Subjects who have uncontrolled or severe illness.
  20. Subjects who have a history of immunodeficiency disease.
  21. infection, active infection including tuberculosis, and infection.
  22. Subjects who have other active which are likely to require the treatment.
  23. female who have positive results in pregnancy test or are lactating.
  24. Subjects who have psychiatric illness or disorders that may preclude study compliance.
  25. Subject who is judged as not eligible to participate in this study by the investigator.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Phase I Dose Escalation Part and Dose Confirmation Part

    Drug: LM-350 for injection

Interventions

  • DrugLM-350 for injection

    Q3W,Intravenous Drip

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limitingtoxicity (DLT)

    Phase I

    Time frame: 78 weeks

  2. Incidence of Treatment-Emergent Adverse Events (AEs)

    Phase I

    Time frame: 78 weeks

  3. Incidence of serious adverse events (SAEs)

    Phase I

    Time frame: 78 weeks

  4. Temperature (Celsius)

    Phase I

    Time frame: 78 weeks

  5. Pulse in BPM(Beat per Minute)

    Phase I

    Time frame: 78 weeks

  6. Blood Pressure in mmHg

    Phase I

    Time frame: 78 weeks

  7. Weight in Kg

    Phase I

    Time frame: 78 weeks

  8. Height in centimeter

    Phase I

    Time frame: 78 weeks

  9. Blood Routine examination -> Complete Blood Count

    Phase I

    Time frame: 78 weeks

  10. Urine Routine examination ->Urinalysis

    Phase I

    Time frame: 78 weeks

  11. Blood Biochemistry test -> Electrolytes and Metabolic Parameters

    Phase I

    Time frame: 78 weeks

  12. Coagulation function test-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT), International normalized

    Phase I

    Time frame: 78 weeks

  13. Pregnancy test

    Phase I

    Time frame: 78 weeks

  14. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage

    Phase I

    Time frame: 78 weeks

  15. 12-lead electrocardiogram (ECG) in HR

    Phase I

    Time frame: 78 weeks

  16. 12-lead electrocardiogram (ECG) in RR

    Phase I

    Time frame: 78 weeks

  17. 12-lead electrocardiogram (ECG) in QRS

    Phase I

    Time frame: 78 weeks

  18. 12-lead electrocardiogram (ECG) in QT

    Phase I

    Time frame: 78 weeks

  19. 12-lead electrocardiogram (ECG) in QTcF

    Phase I

    Time frame: 78 weeks

  20. ECOG(Eastern Cooperative Oncology Group) score

    Phase I

    Time frame: 78 weeks

  21. Objective Response Rate (ORR)

    Phase II

    Time frame: 130 weeks

Secondary outcomes

  1. Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax)

    Phase I/II

    Time frame: 130 weeks

  2. PK Parameter:Time of Maximum Observed Concentration (Tmax)

    Phase I/II

    Time frame: 130 weeks

  3. PK Parameter: Area Under the Concentration-time Curve(AUC)

    Phase I/II

    Time frame: 130 weeks

  4. PK Parameter: Steady State Maximum Concentration(Cmax,ss) PK Parameter: Steady State Maximum Concentration(Cmax,ss)

    Phase I/II

    Time frame: 130 weeks

  5. PK Parameter: Steady State Minimum Concentration(Cmin,ss)

    Phase I/II

    Time frame: 130 weeks

  6. PK Parameter: Systemic Clearance at Steady State (CLss)

    Phase I/II

    Time frame: 130 weeks

  7. PK Parameter: Accumulation Ratio (Rac)

    Phase I/II

    Time frame: 130 weeks

  8. PK Parameter: Elimination Half-life (t1/2)

    Phase I/II

    Time frame: 130 weeks

  9. PK Parameter: Volume of Distribution at Steady-State (Vss)

    Phase I/II

    Time frame: 130 weeks

  10. PK Parameter: Degree of Fluctuation (DF)

    Phase I/II

    Time frame: 130 weeks

  11. Immunogenicity testing->Anti-Drug Antibody test

    Phase I/II

    Time frame: 130 weeks

  12. Objective Response Rate (ORR)

    Phase I

    Time frame: 130 weeks

  13. Duration of Response (DOR) in Month

    Phase I/II

    Time frame: 130 weeks

  14. Disease control rate (DCR) in percentage

    Phase I/II

    Time frame: 130 weeks

  15. Progression-free survival (PFS) in Month

    Phase I/II

    Time frame: 130 weeks

  16. Overall survival (OS) in Month

    Phase I/II

    Time frame: 130 weeks

  17. Changes of target lesions from baseline in Millimeter

    Phase I/II

    Time frame: 130 weeks

  18. Incidence of adverse events (AEs)

    Phase II

    Time frame: 130 weeks

  19. Incidence of serious adverse events (SAEs)

    Phase II

    Time frame: 130 weeks

  20. Temperature (Celsius)

    Phase II

    Time frame: 130 weeks

  21. Pulse in BPM(Beat per Minute)

    Phase II

    Time frame: 130 weeks

  22. Blood Pressure in mmHg

    Phase II

    Time frame: 130 weeks

  23. Weight in Kg

    Phase II

    Time frame: 130 weeks

  24. Height in centimeter

    Phase II

    Time frame: 130 weeks

  25. Blood Routine examination -> Complete Blood Count

    Phase II

    Time frame: 130 weeks

  26. Urine Routine examination ->Urinalysis

    Phase II

    Time frame: 130 weeks

  27. Blood Biochemistry test -> Electrolytes and Metabolic Parameters

    Phase II

    Time frame: 130 weeks

  28. Coagulation function test-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT), International normalized ratio (INR)

    Phase II

    Time frame: 130 weeks

  29. Pregnancy test

    Phase II

    Time frame: 130 weeks

  30. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage

    Phase II

    Time frame: 130 weeks

  31. ECOG(Eastern Cooperative Oncology Group) score

    Phase II

    Time frame: 130 weeks

  32. 12-lead electrocardiogram (ECG) in HR

    Phase II

    Time frame: 130 weeks

  33. 12-lead electrocardiogram (ECG) in RR

    Phase II

    Time frame: 130 weeks

  34. 12-lead electrocardiogram (ECG) in PR

    Phase II

    Time frame: 130 weeks

  35. 12-lead electrocardiogram (ECG) in QRS

    Phase II

    Time frame: 130 weeks

  36. 12-lead electrocardiogram (ECG) in QT

    Phase II

    Time frame: 130 weeks

  37. 12-lead electrocardiogram (ECG) in QTcF

    Phase II

    Time frame: 130 weeks

  38. Biomarker test -> Tumor tissue biomarker test

    Phase I/II

    Time frame: 130 weeks

07

Study locations

3 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2028, 34 months after the start.

Of 195 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 34 months is below that.

Counting every sponsor, half of 297 studies reached it within 60 months; a quarter within 39 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Aug 8, 2025
StartActual
Aug 28, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2030
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07112222
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Aug 28, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Jan 26, 2026

Study contacts

Alex Yuan
Contact
alexyuan@lanovamed.com
+8615901815211

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion